| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Highly multidrug-resistant Acinetobacter species have emerged in medical facilities in Japan and Southeast Asia, and pose a major threat to infectious disease treatment and nosocomial infection control. As a result of this study, it was found that the prophage of multidrug-resistant Acinetobacter species contributed to integrate the 16S rRNA methylase genes and the carbapenem resistance genes into Acinetobacter chromosome and made them highly resistant to aminoglycosides and carbapenems. It was suggested that Acinetobacter species increase the probability of survival to carry drug-resistant factors on the chromosome instead of plasmids on the growth environments.
|
